Environmental-mediated drug resistance: a target for multiple myeloma therapy (Q37810085)

23 August 2017

title

Environmental-mediated drug resistance: a target for multiple myeloma therapy (English)

1 reference

23 August 2017

main subject

multiple drug resistance

1 reference

1 reference

Kenneth H Shain

1

1 reference

23 August 2017

William S Dalton

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2009

1 reference

Expert Review of Hematology

23 August 2017

published in

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

649-662

1 reference

New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression

23 August 2017

cites work

1 reference

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

21 January 2018

1 reference

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

21 January 2018

1 reference

Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis

21 January 2018

1 reference

Stem-cell transplantation for multiple myeloma in the era of novel drugs

21 January 2018

1 reference

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

21 January 2018

1 reference

The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance

21 January 2018

1 reference

Growth factors and antiapoptotic signaling pathways in multiple myeloma

21 January 2018

1 reference

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

21 January 2018

1 reference

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

21 January 2018

1 reference

Tumor microenvironment and drug resistance in hematologic malignancies

21 January 2018

1 reference

Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance

21 January 2018

1 reference

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

21 January 2018

1 reference

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

21 January 2018

1 reference

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.

21 January 2018

1 reference

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.

21 January 2018

1 reference

SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia.

21 January 2018

1 reference

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

Canonical and non-canonical JAK-STAT signaling

21 January 2018

1 reference

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

21 January 2018

1 reference

Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases

21 January 2018

1 reference

The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth

21 January 2018

1 reference

MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism

21 January 2018

1 reference

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

21 January 2018

1 reference

Recent advances in the systemic treatment of metastatic papillary renal cancer

21 January 2018

1 reference

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma

21 January 2018

1 reference

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

21 January 2018

1 reference

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

The myeloproliferative disorders

21 January 2018

1 reference

Role of Stat3 in regulating p53 expression and function

21 January 2018

1 reference

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

21 January 2018

1 reference

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation

21 January 2018

1 reference

Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.

21 January 2018

1 reference

CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells.

21 January 2018

1 reference

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

21 January 2018

1 reference

Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation

21 January 2018

1 reference

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells

21 January 2018

1 reference

Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.

21 January 2018

1 reference

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death

21 January 2018

1 reference

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

21 January 2018

1 reference

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas

21 January 2018

1 reference

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

21 January 2018

1 reference

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

21 January 2018

1 reference

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

21 January 2018

1 reference

A change of strategy in the war on cancer

21 January 2018

1 reference

Mechanisms of drug resistance in cancer chemotherapy

21 January 2018

1 reference

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes

21 January 2018

1 reference

Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense.

21 January 2018

1 reference

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).

21 January 2018

1 reference

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells

21 January 2018

1 reference

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

21 January 2018

1 reference

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

21 January 2018

1 reference

RAD51, genomic stability, and tumorigenesis

21 January 2018

1 reference

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells

21 January 2018

1 reference

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

21 January 2018

1 reference

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

21 January 2018

1 reference

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

21 January 2018

1 reference

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

21 January 2018

1 reference

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

21 January 2018

1 reference

Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside

21 January 2018

1 reference

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma

21 January 2018

1 reference

HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells

21 January 2018

1 reference

Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells

21 January 2018

1 reference

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

21 January 2018

1 reference

Dasatinib in relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

21 January 2018

1 reference

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

21 January 2018

1 reference

Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity

21 January 2018

1 reference

Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.09.55

1 reference

23 August 2017

1 reference